TBPH
Theravance Biopharma
$16.86
$0.00 (0%)Jul 27, 2026
Key metrics
The numbers that frame TBPH today
- Market cap
- $869.18M
- P/E (TTM)
- 7.6
- EV / FCF
- 2.3
- Gross margin
- 100%
- EV / Sales
- 5.7
- ROIC
- 62%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $10.82
- 52wk High
- $21.03
Growth
Revenue and earnings trend for TBPH
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about TBPH
Is Theravance Biopharma a good buy?
Hold. Theravance Biopharma has mixed quality and strong momentum. The setup is mixed. Growth looks weak. That could put pressure on the long-term business case. We think Theravance Biopharma is selling at a low price.
What is the market capitalization of TBPH?
Theravance Biopharma's market capitalization is $869.18M.
What is the P/E ratio for TBPH stock?
Theravance Biopharma's current P/E ratio is 7.6.
What is the 52-week high for TBPH stock?
The 52-week high for Theravance Biopharma is $21.03. The current close of $16.86 is 19.8% below that high.
What is the 52-week low for TBPH stock?
The 52-week low for Theravance Biopharma is $10.82. The current close of $16.86 is 55.8% above that low.
Does TBPH stock pay dividends?
Theravance Biopharma does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TBPH?
Theravance Biopharma's Debt / Equity ratio is 0.14.